Department of Cardiology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, PR China.
Department of Cardiology, The First Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, PR China.
Life Sci. 2017 Mar 15;173:20-27. doi: 10.1016/j.lfs.2017.01.013. Epub 2017 Feb 1.
Pharmacological treatment of prehypertension may ameliorate hypertension and improve vascular structure and function. This study investigated 1) whether early treatment with either losartan or amlodipine at the onset of prehypertension can prevent hypertension and 2) whether losartan and amlodipine equally improve vascular remodeling and function in a rat model of hypertension.
Stroke-prone spontaneously hypertensive (SHRSP) rats were administered losartan, amlodipine or saline for 6 or 16weeks at the onset of prehypertension. Wistar-Kyoto rats were used as a control. All groups were observed for 40weeks. Systolic blood pressure was measured using the tail-cuff method. Vascular structure and function were determined by microscopy and vascular ring contractility assays, respectively. Angiotensin II (Ang II) and aldosterone (Aldo) were measured by radioimmunoassays. Angiotensin II type 1 receptor (AT1R) and angiotensin II type 2 receptor (AT2R) expression was measured by western blot.
Losartan effectively reduced progression from prehypertension to hypertension as well as vascular remodeling and improved vascular contractility in SHRSP rats. Long-term losartan (16weeks) had greater benefits than short-term (6weeks) treatment. Losartan increased Ang II and decreased Aldo levels in the serum and vessel walls of resistance vessels in a time-dependent manner. Losartan significantly decreased AT1R and increased AT2R vascular expression. Amlodipine had no effect on vascular AT1R and AT2R expression.
Losartan administered at the onset of prehypertension is more effective than amlodipine in ameliorating hypertension and improving vascular remodeling and function, which is likely mediated by the renin-angiotensin-aldosterone system.
对高血压前期进行药物治疗可能改善高血压,并改善血管结构和功能。本研究旨在:1)观察在高血压前期早期开始使用氯沙坦或氨氯地平治疗是否可以预防高血压;2)观察氯沙坦和氨氯地平是否同样能改善高血压大鼠模型的血管重构和功能。
自发性高血压脑卒中易发性(SHRSP)大鼠在高血压前期开始时给予氯沙坦、氨氯地平或生理盐水治疗 6 或 16 周。Wistar-Kyoto 大鼠作为对照。所有组大鼠均观察 40 周。使用尾套法测量收缩压。通过显微镜和血管环收缩性测定分别确定血管结构和功能。使用放射免疫分析法测量血管紧张素 II(Ang II)和醛固酮(Aldo)。通过 Western blot 测量血管紧张素 II 型 1 受体(AT1R)和血管紧张素 II 型 2 受体(AT2R)的表达。
氯沙坦能有效减少从高血压前期进展为高血压,还能减少血管重构,并改善 SHRSP 大鼠的血管收缩性。与短期(6 周)治疗相比,长期(16 周)的氯沙坦治疗效果更好。氯沙坦能在时间依赖性方式下降低血清和阻力血管壁中的 Ang II,增加 Aldo 水平。氯沙坦能显著降低血管 AT1R,并增加 AT2R 的血管表达。氨氯地平对血管 AT1R 和 AT2R 表达无影响。
在高血压前期早期开始使用氯沙坦比氨氯地平更能有效改善高血压,并改善血管重构和功能,这可能是通过肾素-血管紧张素-醛固酮系统介导的。